Readiness for Bispecific Antibody Therapy: Initiation and Maintenance Phases
Editor-in-Chief: Krista Nelson, LCSW, OSW-C, FAOSW, FAPOS, FACCC Oncology Issues, Article, Volume 39, Over the last 2 decades, the development of bispecific antibodies (BsAbs) has revolutionized cancer treat-ment. 1 Developed to address drug resistance and to improve treatment safety and efficacy, bispecific antibodies have 2 distinct binding domains that can bind to 2 antigens or epitopes simultaneously. Although BsAbs are a promising new therapeutic approach, especially for hematologic malignancies in